Artofchart

Accumulate, Hold for Long term

做多
NSE:STAR   STRIDES PHARMA SCI
Excellent Opportunity to buy the stock. Strides revenues in Q4FY21 grew by 47% YoY to Rs.908 cr during the quarter with sales growth in the regulated markets and emerging markets.

I have entered around the 770 mark as Investment and plan to hold for long term

Chart study, not a call
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。